Rojas-Martínez Carmen, Lira-Amaya José J, Ueti Massaro W, Castañeda-Arriola Roberto O, Millán Julio V Figueroa, Martínez Jesús A Álvarez
Babesia Unit-CENID-Salud Animal e Inocuidad, INIFAP, Carretera Federal, Cuernavaca-Cuautla No. 8534, Col. Progreso, Jiutepec C.P. 62550, Morelos, Mexico.
Agricultural Research Service-Animal Disease Research Unit, The US Department of Agriculture, Pullman, WA 99164, USA.
Pathogens. 2025 May 20;14(5):498. doi: 10.3390/pathogens14050498.
This study evaluated the effects of various concentrations of PVP-40 on the in vitro cryopreservation and recovery of and . We also assessed a reduced dose of attenuated strains to determine its efficacy in preventing clinical disease. A microaerophilic stationary phase blood culture system was used to recover parasites that were cryopreserved in solutions with various PVP-40 concentrations and parasites in 20% PVP-40 were used to vaccinate naïve cattle. The animals were vaccinated intramuscularly with frozen parasites cryopreserved in 20% PVP-40, with a dose of either 1 × 10 or 1 × 10 erythrocytes infected with both attenuated and produced from blood cultures. The control group received uninfected erythrocytes. During the vaccination, clinical parameters such as rectal temperature and hematocrit levels were unaffected. The animals were relocated to a farm in a hyperendemic area to test the efficacy of these live vaccines in controlling disease onset. Some vaccinated animals showed mild disease. In the vaccinated groups, parasites were detected in blood smears for only one day during the challenge. In contrast, the control group experienced fever for three consecutive days, a decline in hematocrit levels, and significant health deterioration. In this group, parasites were detected in smears for four consecutive days. All the animals in the control group required treatment to manage their high parasitemia and prevent mortality. In this study, we demonstrated that increasing the concentration of PVP-40 to cryopreserve parasites improved the recovery and proliferation of spp. in blood culture, and we also showed that when animals were vaccinated with cryopreserved, in vitro cultured, attenuated parasites in 20% PVP-40, they were effectively protected from severe clinical babesiosis.
本研究评估了不同浓度的聚乙烯吡咯烷酮-40(PVP-40)对[具体寄生虫名称1]和[具体寄生虫名称2]体外冷冻保存及复苏的影响。我们还评估了减毒[寄生虫名称3]菌株的较低剂量,以确定其预防临床疾病的效果。使用微需氧静止期血液培养系统来复苏保存在含有不同PVP-40浓度溶液中的[寄生虫名称1]寄生虫,并使用保存在20% PVP-40中的[寄生虫名称2]寄生虫对未感染的牛进行疫苗接种。用保存在20% PVP-40中的冷冻寄生虫对动物进行肌肉注射,剂量为1×10⁶或1×10⁷个感染了减毒[寄生虫名称3]和从血液培养物中产生的[寄生虫名称4]的红细胞。对照组接受未感染的红细胞。在疫苗接种期间,直肠温度和血细胞比容水平等临床参数未受影响。将动物转移到一个[寄生虫名称5]高度流行地区的农场,以测试这些活疫苗在控制疾病发作方面的效果。一些接种疫苗的动物出现了轻度疾病。在接种疫苗的组中,在攻毒期间血液涂片仅在一天内检测到寄生虫。相比之下,对照组连续三天发烧,血细胞比容水平下降,健康状况明显恶化。在该组中,涂片连续四天检测到寄生虫。对照组的所有动物都需要治疗以控制其高寄生虫血症并预防死亡。在本研究中,我们证明增加PVP-40浓度以冷冻保存寄生虫可提高[寄生虫属名]在血液培养中的复苏和增殖,并且我们还表明,当用保存在20% PVP-40中的体外培养的减毒[寄生虫名称6]寄生虫对动物进行疫苗接种时,它们能有效预防严重的临床巴贝斯虫病。